Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-21231
Publication type: Article in scientific journal
Type of review: Peer review (publication)
Title: QTc prolongation after haloperidol administration in critically ill patients post cardiovascular surgery : a cohort study and review of the literature
Authors: Burbuqe, Ibrahimi
Boettger, Soenke
Schubert, Maria
Bettex, Dominique
Rudiger, Alain
et. al: No
DOI: 10.1017/S1478951520000231
10.21256/zhaw-21231
Published in: Palliative & Supportive Care
Volume(Issue): 18
Issue: 4
Page(s): 447
Pages to: 459
Issue Date: 29-Apr-2020
Publisher / Ed. Institution: Cambridge University Press
ISSN: 1478-9515
1478-9523
Language: English
Subjects: Cardiac surgery; Delirium; Haloperidol; ICU; Long QT; QTc time
Subject (DDC): 616: Internal medicine and diseases
Abstract: Objective: From case reports, haloperidol administration has been associated with QTc prolongation, torsades de pointes, and sudden cardiac death. In a vulnerable population of critically ill patients after cardiac surgery, however, it is unclear whether haloperidol administration affects the QTc interval. Thus, the aim of this study is to explore the effect of haloperidol in low doses on this interval. Method: This retrospective cohort study was performed on a cardio-surgical intensive care unit (ICU), screened 2,216 patients and eventually included 68 patients with delirium managed with oral and intravenous haloperidol. In this retrospective analysis, electrocardiograms were taken prior and within 24 h after haloperidol administration. The effect of haloperidol on QTc was determined with a Person correlation, and inter-group differences were measured with new long QT comparisons. Results: In total, 68 patients were included, the median age was 71 (64–79) years and predominantly male (77%). Haloperidol administration followed ICU admission by three days and the cumulative dose was 4 (2–9) mg. As a result, haloperidol administration did not affect the QTc (r = 0.144, p = 0.23). In total, 31% (21/68 patients) had a long QT before and 27.9% (19/68 patients) after haloperidol administration. Only 12% (8/68 patients) developed a newly onset long QT. These patients were not different in the route of administration, cumulative haloperidol doses, comorbidities, laboratory findings, or medications. Significance of results: These results indicated that low-dose intravenous haloperidol was safe and not clinically relevant for the development of a newly onset long QT syndrome or adverse outcomes and support recent findings inside and outside the ICU setting.
Further description: Erworben im Rahmen der Schweizer Nationallizenzen (http://www.nationallizenzen.ch)
URI: https://digitalcollection.zhaw.ch/handle/11475/21231
Fulltext version: Published version
License (according to publishing contract): Licence according to publishing contract
Restricted until: 2026-01-01
Departement: School of Health Sciences
Organisational Unit: Institute of Nursing (IPF)
Appears in collections:Publikationen Gesundheit



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.